Related Experiment Video
Updated: Feb 22, 2026
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Abstract:
The genomic-plasticity of the immune system creates a broad immune repertoire engaged to tackle cancer cells. Promising clinical activity has been observed with several immune therapy strategies in solid tumors including melanoma, lung, kidney, and bladder cancers, albeit as yet immunotherapy-based treatment approaches in pancreatic ductal adenocarcinoma (PDAC) remain to have proven value. While translational and early clinical studies have demonstrated activation of antitumor immunity, most recent late-phase clinical trials have not confirmed the early promise in PDAC except in MSI-High PDAC patients. These results may in part be explained by multiple factors, including the poorly immunogenic nature of PDAC along with immune privilege, the complex tumor microenvironment, and the genetic plasticity of PDAC cells. These challenges have led to disappointments in the field, nonetheless they have also advanced our understanding that may tailor the future steps for immunotherapy for PDAC. Therefore, there is significant hope that progress is on the horizon.
Insights
Immunotherapy shows promise in many cancers but faces challenges in pancreatic ductal adenocarcinoma (PDAC). Further research into PDAC
Area of Science:
- Oncology
- Immunology
Background:
- The immune system's genomic plasticity enables a broad repertoire for cancer cell targeting.
- Immunotherapy has shown clinical success in solid tumors like melanoma, lung, kidney, and bladder cancers.
Purpose of the Study:
- To evaluate the efficacy of immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
- To understand the challenges and potential future directions for PDAC immunotherapy.
Main Methods:
- Review of translational and late-phase clinical trials for immunotherapy in PDAC.
- Analysis of factors contributing to PDAC's resistance to immunotherapy.
Main Results:
- Early clinical studies showed antitumor immunity activation in PDAC.
- Late-phase trials did not confirm early promise, except in MSI-High PDAC patients.
- PDAC's poor immunogenicity, immune privilege, complex tumor microenvironment, and genetic plasticity hinder immunotherapy efficacy.
Conclusions:
- Despite setbacks, research has advanced understanding of PDAC immunotherapy.
- Future strategies may be tailored to overcome PDAC-specific challenges.
- There is hope for future progress in PDAC immunotherapy.
More Related Videos
08:30Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
Published on: October 9, 2018
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
